Active, not recruitingNCT07448493
Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Blokhin's Russian Cancer Research Center
- Principal Investigator
- David Khalafyan, MDBlokhin's Russian Cancer Research Center
- Intervention
- Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR)(procedure)
- Enrollment
- 230 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2027
Study locations (15)
- Gomel Regional Clinical Oncology Dispensary (OKOD), Homyel, Belarus
- Kaliningrad Regional Clinical Oncology Center, Kaliningrad, Russia
- Moscow Regional Oncology Hospital No. 62, Krasnogorsk, Russia
- A.S. Loginov Moscow Clinical Scientific Center, Moscow, Russia
- S.S. Yudin City Clinical Hospital, Oncology Center No. 1, Moscow, Russia
- Blokhin's Russian Cancer Research Center, Moscow, Russia
- OncoStop CyberKnife Center, Moscow, Russia
- Moscow Multidisciplinary Clinical Center "Kommunarka", Moscow, Russia
- Gamma Knife Center Moscow, Moscow, Russia
- N.N. Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia
- P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
- N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
- Federal Center of Neurosurgery, Tyumen, Russia
- Republican Clinical Oncology Dispensary (RCOD), Ufa, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07448493 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
- RECRUITINGPHASE2NCT06808971Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJCancer Institute and Hospital, Chinese Academy of Medical Sciences
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →